Bezisterim

Summary

Bezisterim (CHEMBL4297284) is a phase-3 clinical-stage protein; indicated across 9 conditions including alzheimer disease and type 2 diabetes mellitus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 9 conditions
• Clinical trials: 11
• Chemistry: 330.5 Da · C21H30O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297284
Name	Bezisterim
Type	Protein
Max phase	3
FDA approved	no
PubChem CID	16739648
Molecular formula	C21H30O3
Molecular weight	330.5
InChIKey	JJKOQZHWYLMASZ-FJWDNACWSA-N

SMILES: C[C@]12CC[C@@H](CC1=C[C@@H]([C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C)O)O

IUPAC name: (3S,7R,8R,9S,10R,13S,14S,17R)-17-ethynyl-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,7,17-triol

Also known as: Bezisterim, HE 3286, HE-3286, He3286, HE3286, NE 3107, NE-3107, Ne3107, Triolex, BEZISTERIM

Patent coverage: 108 distinct patent families (354 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Alzheimer disease	3	MONDO:0004975	MONDO:0004975
type 2 diabetes mellitus	2	MONDO:0005148	MONDO:0005148
brain injury	2	MONDO:0043510	MONDO:0043510
rheumatoid arthritis	1	MONDO:0008383	EFO:0000685
ulcerative colitis	1	MONDO:0005101	EFO:0000729
autoimmune disorder of central nervous system	1	MONDO:0000568	EFO:0020092
Parkinson disease	1	MONDO:0005180	MONDO:0005180

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE2	5
PHASE1/PHASE2	3
PHASE1	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04669028	PHASE3	COMPLETED	A Phase 3 Study of NE3107 in Probable Alzheimer’s Disease
NCT06757010	PHASE2	ACTIVE_NOT_RECRUITING	A Study of NE3107 in Early Parkinson’s
NCT06847191	PHASE2	ACTIVE_NOT_RECRUITING	NE3107 in Adults With Neurological Symptoms of Long COVID
NCT00628433	PHASE1/PHASE2	COMPLETED	Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
NCT00694057	PHASE2	COMPLETED	Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus
NCT00712114	PHASE1/PHASE2	COMPLETED	Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid Arthritis
NCT05083260	PHASE1/PHASE2	COMPLETED	NE3107 Activity and Safety in Patients With Parkinson’s Disease Using Levodopa
NCT05227820	PHASE2	COMPLETED	Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of Dementia
NCT05970575	PHASE2	TERMINATED	Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury
NCT00555451	PHASE1	COMPLETED	Safety, Pharmacokinetics and Potential Activity of HE3286 in Obese Adult Subjects
NCT00991107	PHASE1	COMPLETED	A Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).